UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 14, 2014

LEXARIA CORP.

(Exact name of registrant as specified in its charter)

000-52138

Nevada (State or other jurisdiction of incorporation)

(Commission File Number)

20-2000871 (IRS Employer Identification No.)

#950 - 1130 West Pender Street, Vancouver, British Columbia, Canada V6E 4A4

Registrant's telephone number, including area code: (604) 602-1675

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e -4(c))

Item 1.01 Entry into a Material Agreement

Item 3.02 Unregistered Sales of Equity Securities

The Company appointed Mr. Jeff Paikin to its Advisory Board for a period of not less than one year, but to be determined by certain performance thresholds described in the letter. Upon signing of the letter of acceptance the Company issued 110,000 common shares at a deemed price of \$0.39. Based on the milestones listed in the letter, Mr. Paikin can be eligible to receive up to a total of 525,000 common shares of the Company.

The Company issued the 110,000 common shares at a deemed price of \$0.39 per the terms of the Letter to one (1) non-US persons in an off-shore transaction pursuant to the exemption from registration provided for under Regulation S, promulgated under the United States Securities Act of 1933, as amended.

The securities referred to herein will not be and have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Item 7.01 Regulation FD Disclosure.

A copy of the news release announcing the appointment is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.	Description
10.1	Letter of Appointment dated April 14, 2014
<u>99.1</u>	Press Release dated April 14, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 14, 2014

Lexaria Corp.

(Signature) By: <u>"/s/ Chris Bunka"</u> Chris Bunka President & CEO



Mr. Jeff Paikin 400-69 John St. South Hamilton, ON L8N 2B9 P - <u>905-777-0000</u>

April 10, 2014

Dear Mr. Paikin,

This letter confirms your appointment to, and your acceptance of, your role as a member of Lexaria Corp.'s Advisory Board for a period of not less than one year, but to be determined by certain performance thresholds as noted below.

As an advisor to Lexaria Corp, you agree to make available to the Board of Directors of Lexaria and to myself as President/CEO of Lexaria, your time and expertise as required to assist us to evaluate opportunities and procedures in the legal marijuana sector. We would expect your expertise in the areas of project evaluation; building selection; finance and such other areas as you feel best represent your abilities.

In return for your agreeing to assist us in this manner, we will pay to you the following schedule of compensation for your participation on our Advisory Board, to a total of 525,000 restricted common shares. Any/all shares issued must be in compliance with all Canadian and US regulations, and you must remain a member of our Advisory Board at the time of each compensation award.

The table below represents milestones to be achieved at the building location known to you and to Lexaria Corp, but not disclosed herein due to reasons of competitiveness within the industry. It is understood that the plant will be outfitted and designed to produce medical marijuana under Health Canada's MMPR program.

Shares On Signing	Shares On Municipal Approval	Shares On Health Canada Approval	Shares on First Harvest	Shares on \$5,000,000 in Plant Revenue
110,000	55,000	110,000	165,000	137,500

We very much appreciate your time and expertise and believe you can make a valuable contribution to Lexaria's success.

If this is acceptable to you, please sign this letter as specified below, and return to me via scan at bossbunka@gmail.com, at your earliest convenience.

Yours Truly,

Chris Bunka CEO Lexaria Corp

Accepted: Jeff Paikin

Lexaria Corp. 156 Valleyview Road Kelowna BC V1X3M4 Phone 250.765.6424 info@lexariaenergy.com

NEWS RELEASE

Lexaria Welcomes Jeff Paikin to Advisory Board

Kelowna, BC—April 14, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce the appointment of a new expert to its Advisory Board.

Mr. Jeff Paikin has joined Lexaria's Advisory Board. Mr Paikin is well known throughout the Greater Toronto area as the President of New Horizon Development Group and for his extensive community involvement. Mr. Paikin is the past Chair and a current Board Member of the Canadian Accredited Independent Schools; a member of the Hamilton Tiger-Cats Advisory Board, and for 29 years has been on the Committee of B'Nai Brith Sports Celebrity Dinner in Hamilton, ON.

Mr. Paikin was named Hamilton's Royal Bank of Canada Distinguished Citizen of the Year for 2013. He is a past Member of the Campaign Cabinet for The Children's Aid Society and of the Hamilton Health Sciences Foundation, among many others.

"Lexaria is taking a professional and appropriate step-by-step methodical approach to building its medical marijuana business," said Mr. Paikin. "I'm excited to be part of this new industry at its formative stage."

Mr. Paikin is eligible to receive up to 525,000 restricted common shares of stock over time in his role as an Advisory Board member, depending on certain specified performance thresholds being reached. Lexaria continues to build its team of experts and consultants in all aspects of its business and expects to continue this growth in the near future.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria's shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company involves itself in projects that could provide above-market returns and has a long history of regulatory compliance in both the USA and Canada.

To learn more about Lexaria Corp. visit www.lexariaenergy.com. FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp. Chris Bunka Chairman & CEO (250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," 'expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the medical marijuana business or any member of the Advisory Board will provide any benefit to Lexaria.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.